A Prognostic Impact of Splenectomy in Laparoscopic Distal Pancreatectomy on Benign/Borderline Pancreatic Tumors: A Change of the Era

Seung Soo Hong1,2, Sung Whan Cha3, Ho Kyoung Hwang1,2, Woo Jung Lee1,2, and Chang Moo Kang1,2

1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul; 2Pancreatobiliary Cancer Center, Yonsei Cancer Center, Severance Hospital, Seoul; 3Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea.

Purpose: In the past, spleen preservation during distal pancreatectomy (DP) was preferred; however, more recent studies reported comparable results between splenectomy and spleen preserving. We retrospectively reviewed patients in a single center who underwent laparoscopic DP with/without splenectomy, and evaluated the chronologic changes of surgical outcomes of the two procedures.

Materials and Methods: Patients who underwent laparoscopic DP with or without splenectomy due to benign/borderline tumor from 2005 to 2019 were included in this study. We divided this period into Era 1 (2005–2012) and Era 2 (2013–2019), and compared the chronological evolution of surgical outcomes of laparoscopic distal pancreatectosplenectomy (LDPS) to those of laparoscopic spleen-preserving distal pancreatectomy (LSpDP), including the long-term postoperative immunologic profiles.

Results: A total of 198 cases were included (LSpDP: 80 cases; LDPS: 118 cases). As the period changed from Era 1 to Era 2, the ratio of LSpDP decreased and the surgical outcomes of LDPS improved. In Era 1, LSpDP group showed superior results compared to LDPS group in terms of hospital days and postoperative pancreatic fistula ratio; however, in Era 2, the surgical outcomes showed no statistical differences. No significant differences were observed in all of the immunologic markers.

Conclusion: We carefully conclude that during laparoscopic DP, combined splenectomy can be equivalent to spleen preserving in surgical and immunological outcomes, and inevitable splenectomy can be safely conducted.

Key Words: Laparoscopic, distal pancreatectomy, spleen preserving, chronologic change, surgical outcomes

INTRODUCTION

Minimally-invasive spleen-preserving distal pancreatectomy (DP) is indicated for benign or borderline malignant lesions confined to the pancreatic body and tail. Resection of the pancreatic body at any point left of the portal vein is termed DP, and is traditionally combined with splenectomy (distal pancreatectosplenectomy, DPS).1 The effect of spleen preservation during laparoscopic DP remained controversial for past a few decades.2 Two surgical techniques are available to preserve the spleen. First, Warshaw described a technique in which splenic vessels are ligated with the preservation of the short gastric and left gastroepiploic vessels. Second, the operation can also be performed by sparing the splenic vessels, which assures increased blood supply to the spleen.3

Until the early 2000s, many papers have been published demonstrating the superior results of laparoscopic spleen-preserving DP compared to DPS.

Shoup, et al.4 reported that in the comparison of splenectomy-
my (n=79) and splenic preservation groups (n=46), the splenectomy group showed higher incidence of infectious and more severe complications (Clavien-Dindo classification Grade III or IV) and longer hospital stay. They insisted that splenic preservation should be considered in benign and low-grade malignant disease. However, this conclusion was driven from old data, compiled from the 1980s to early 2000, and should be reevaluated, as recent surgical techniques of laparoscope and postoperative management have improved and surgical complication has decreased.

Recent studies reported more comparable results between splenectomy and spleen preserving groups. Milito, et al. reported the impact of spleen-preserving laparoscopic DP on postoperative infectious complications via systematic review and meta-analysis. In their study, 632 patients in 10 observational studies were included. In the splenectomy group (n=296), there was more significant risk of postoperative surgical site infection [odds ratio (OR)=2.30, p=0.048], overall complications (OR=1.51, p=0.048), and open conversion rate (OR=3.15, p=0.005). However, in hospital stay, pancreatic fistula, postoperative bleeding, and reoperation rate showed no statistical differences between the two groups. They concluded that these results should be interpreted with caution, and further studies should be performed.

These contradictory results according to chronologic changes have led to the need for re-evaluation of how splenectomy affects surgical outcomes. In this respect, we retrospectively reviewed patients in a single center who underwent laparoscopic DP with/without splenectomy, and evaluated the chronologic changes of surgical outcomes of the two procedures.

MATERIALS AND METHODS

Patient selection
We retrospectively reviewed patients who underwent laparoscopic DP with/without splenectomy due to benign or borderline malignant tumor from 2005 to 2019 in Severance Hospital, Seoul, Korea. We divided this period into Era 1 (2005–2012) and Era 2 (2013–2019), and compared the chronologic evolution of surgical outcomes of laparoscopic distal pancreatectomy (LSpDP) to those of laparoscopic spleen-preserving distal pancreatectomy (LDPS). Surgical outcomes consisted of the overall complication, postoperative pancreatic fistula (POPF), operation time, length of hospital stay (LOH), estimated blood loss (EBL), and transfusion. We also compared the long-term postoperative immunologic profiles of patients using immunologic markers. Lambda-chain, Kappa-chain, IgA, IgM, and IgG were used as immunologic markers. This study was approved by the Institutional Review Board of Yonsei University College of Medicine (4-2020-0983).

Statistical analysis
All statistical analyses were performed using Statistical Package for Social Sciences, version 23 (SPSS, IBM Corp., Armonk, NY, USA). Values are expressed as means and standard deviations or medians and ranges, as appropriate. Categorical variables were compared using the chi-square test and reported as number and percentage (%). Chi-square linear-by-linear association was used to analyze the frequency of LSpDP and LDPS by year. Continuous variables were compared using the independent t-test or the Mann–Whitney test, as appropriate. The p-value for statistical significance was set at 0.05.

RESULTS

Chronological change of laparoscopic DP
A total of 190 cases were included in this study, consisting of 80 cases in LSpDP group and 118 cases in LDPS group. In Era 1, 40 cases were in LSpDP group and 43 cases in LDPS group. In Era 2, 50 cases were in LSpDP group and 75 cases in LDPS group.

| Era 1 (2005–2012): n=83 | Era 2 (2013–2019): n=115 |
|-------------------------|-------------------------|
| LSpDP group (n=40)      | LSpDP group (n=40)      |
| vs.                     | vs.                     |
| LDPS group (n=43)       | LDPS group (n=75)       |

Fig. 1. Patient selection. A total of 198 cases were included in this study, consisting of 80 cases in LSpDP group and 118 cases in LDPS group. In Era 1, 40 cases were in LSpDP group and 43 cases in LDPS group. In Era 2, 50 cases were in LSpDP group and 75 cases in LDPS group. LSpDP, laparoscopic spleen-preserving distal pancreatectomy; LDPS, laparoscopic distal pancreatectomy.

Fig. 2. Number of cases according to the year. Except for 2005 and 2006, in Era 1, LSpDP showed a similar or higher frequency compared to LDPS; but as the period got closer to Era 2, the ratio of LSpDP began to decrease (Era 1: p=0.127, Era 2: p=0.003). LSpDP, laparoscopic spleen-preserving distal pancreatectomy; LDPS, laparoscopic distal pancreatectomy.
In Era 2, 40 cases were in LSpDP group and 75 cases in LDPS group (Fig. 1). We analyzed the frequency of LSpDP and LDPS by year. Except for 2005 and 2006, in Era 1, LSpDP showed a similar or higher frequency compared to LDPS; but as the period got closer to Era 2, the ratio of LSpDP began to decrease (Era 1: \( p=0.127 \); Era 2: \( p=0.003 \)) (Fig. 2).

**Chronological change in perioperative outcomes of LDPS**

To evaluate the chronic changes of LDPS, we compared the clinical characteristics and surgical outcomes of LDPS during Era 1 and Era 2 (Table 1). We found that the surgical outcomes of LDPS improved according to the chronological change. There were no statistical differences in age, sex, body mass index (BMI), diagnosis, and tumor size between the two periods. However, the LOH decreased from 12.0 to 9.1 days (\( p=0.044 \)), EBL decreased from 259.8 to 144.5 mL (\( p=0.011 \)), and transfusion rate decreased from 9.3% to 0.0% (\( p=0.016 \)).

In terms of postoperative complications, the overall complication rate did not show difference between the two periods (\( p=0.843 \)); however, the ratio of clinically relevant (CR) complications (Clavien-Dindo classification grade III or IV) decreased from 16.3% to 4.0% (\( p=0.027 \)). Also, in POPF, the total ratio did not differ between the two groups (\( p=0.197 \)), but CR-POPF decreased significantly (\( p=0.050 \)) from 14.0% to 2.7%.

**Chronological change in perioperative outcomes between LDPS and LSpDP**

In Era 1, there was no difference in clinical characteristics between the two groups. However, it was noted that LSpDP group showed superior results compared to LDPS group in terms of LOH (8.8 days vs. 12.0 days, \( p=0.043 \)) and POPF ratio (22.5% vs. 44.2%, \( p=0.037 \)) (Table 2).

In Era 2, clinical characteristics between the two groups did not show statistical difference (Table 2). However, the surgical outcomes showed better results in LSpDP group than LDPS group. The operation time (\( p=0.003 \)), hospital stay (\( p=0.043 \)), estimated blood loss (\( p=0.037 \)), and other complications (\( p=0.016 \)) were significantly lower in LSpDP group. Also, the ratio of CR-POPF decreased from 14.0% to 2.7%.

---

**Table 1. Clinical Characteristics and Surgical Outcomes of LDPS according to Era**

| Era 1: 2005-2012 (n=43) | Era 2: 2013-2019 (n=75) | \( p \) value |
|--------------------------|------------------------|----------------|
| **Clinical characteristics** |                        |                |
| Age (yr) | 50.07±14.61 | 53.11±15.65 | 0.301 |
| Sex, male | 15 (34.9) | 27 (36.0) | 0.903 |
| BMI (kg/m\(^2\)) | 22.84±3.08 | 24.07±3.61 | 0.061 |
| **Diagnosis** | 0.244 |                |
| IPMN | 9 | 14 |
| NET | 4 | 18 |
| SPN | 10 | 11 |
| MCN | 7 | 6 |
| SCN | 5 | 5 |
| Metastatic cancer | 2 | 4 |
| Chronic pancreatitis | 4 | 5 |
| Other benign | 2 | 10 |
| Other cancer | 0 | 2 |
| Tumor size (cm) | 3.75±1.80 | 3.69±2.26 | 0.899 |

| Surgical outcomes |
|-------------------|
| Operation time (min) | 218.4±108.6 | 216.2±88.7 | 0.908 |
| Hospital stay (days) | 12.0±8.8 | 9.1±3.8 | 0.044* |
| Estimated blood loss (mL) | 259.8±261.1 | 144.5±161.7 | 0.011* |
| Transfusion | 4 (9.3) | 0 (0.0) | 0.016* |
| Complication | 18 (41.9) | 30 (40.0) | 0.843 |
| G1+G2 | 11 (25.6) | 27 (36.0) | 0.027* |
| G3+G4 | 7 (16.3) | 4 (4.0) |                |
| POPF | 19 (50.0) | 28 (37.3) | 0.197 |
| CR-POPF | 6 (14.0) | 2 (2.7) | 0.050* |

LDPS, laparoscopic distal pancreatectomy; IPMN, intraductal papillary mucinous neoplasm; NET, neuroendocrine tumor; SPN, solitary pseudopapillary neoplasm; MCN, mucinous cystic neoplasm; SCN, serous cystic neoplasm; POPF, postoperative pancreatic fistula; BMI, body mass index; CR-POPF, clinically relevant POPF.

*Statistically significant.

Data are presented as mean±standard deviation, n (%), or number only.

---

**Table 2. Clinical Characteristics and Surgical Outcomes of Two Groups in Era 1**

|                      | LSpDP (n=40) | LDPS (n=43) | \( p \) value |
|----------------------|--------------|-------------|---------------|
| **Clinical characteristics** |              |             |               |
| Age (yr) | 55.08±13.97 | 50.07±14.61 | 0.115 |
| Sex, male | 13 (32.5) | 15 (34.9) | 0.818 |
| BMI (kg/m\(^2\)) | 23.26±3.40 | 22.84±3.08 | 0.550 |
| **Diagnosis** | 0.762 |                |
| IPMN | 12 | 9 |
| NET | 6 | 4 |
| SPN | 9 | 10 |
| MCN | 4 | 7 |
| SCN | 6 | 5 |
| Metastatic cancer | 1 | 2 |
| Chronic pancreatitis | 1 | 4 |
| Other benign | 1 | 2 |
| Other cancer | 0 | 0 |
| Tumor size (cm) | 3.01±2.25 | 3.75±1.80 | 0.146 |

| **Surgical outcomes** |
|-----------------------|
| Operation time (min) | 224.3±83.9 | 218.4±108.6 | 0.784 |
| Hospital stay (days) | 8.8±6.6 | 12.0±8.8 | 0.043* |
| Estimated blood loss (mL) | 239.8±382.8 | 259.8±261.1 | 0.780 |
| Transfusion | 4 (10.0) | 4 (9.3) | >0.999 |
| Complication | 12 (30.0) | 18 (41.9) | 0.261 |
| G1+G2 | 9 (22.5) | 11 (25.6) | 0.694 |
| G3+G4 | 3 (7.5) | 7 (16.3) |                |
| POPF | 9 (22.5) | 19 (44.2) | 0.037* |
| CR-POPF | 3 (7.5) | 6 (14.0) | 0.485 |

LSpDP, laparoscopic spleen-preserving distal pancreatectomy; LDPS, laparoscopic distal pancreatectomy; BMI, body mass index; IPMN, intraductal papillary mucinous neoplasm; NET, neuroendocrine tumor; SPN, solitary pseudopapillary neoplasm; MCN, mucinous cystic neoplasm; SCN, serous cystic neoplasm; POPF, postoperative pancreatic fistula; CR-POPF, clinically relevant POPF.

*Statistically significant.

Data are presented as mean±standard deviation, n (%), or number only.
not differ, except for BMI. The BMI in LDPS group was higher than that in LSpDP group (24.07 kg/m² vs. 22.55 kg/m², p=0.031). However, the surgical outcomes showed no statistical differences between the two groups (Table 3).

**DISCUSSION**

The treatment of choice for benign and borderline malignant pancreatic tumor in pancreas body and tail is DP, and recently, most operations are conducted using the laparoscopic approach.6-9 However, due to the technical complexity and anatomical proximity, combined splenectomy is occasionally conducted without any relation to oncologic outcomes.10 In this study, we planned concomitant splenectomy preoperatively, if any of the following findings were found on the preoperative imaging study: the tumor abuts splenic hilum or splenic vessels; the splenic vessel is tortuous and has multiple branches; or the pancreas tail abuts splenic hilum, so vessel dissection would be difficult. In our study, we conducted completion of splenectomy in case of total splenic ischemia after Warshaw’s procedures.

The impact of splenectomy on surgical outcomes still remains controversial, since the function of spleen is not well-known, excluding immunological functions.11 A few decades ago, severe complications, such as overwhelming post-splenectomy infection, were occasionally observed;12 however, due to the advance in postoperative care, most recent patients do not experience complications after splenectomy.

Some recent studies reported equivalent surgical outcomes between LDPS and LSpDP. In 2014, Dumitrascu, et al.13 reported that spleen removal during DP was not associated with a higher morbidity but with an increased blood loss and the need for intraoperative transfusions. Although the postoperative systemic inflammatory response was higher when the splenectomy was performed, the number of postoperative infectious complications was not influenced. In 2016, Kwon, et al.14 reported that LDPS was associated with more fluid collec-

---

**Table 3. Clinical Characteristics and Surgical Outcomes of Two Groups in Era 2**

|                          | LSpDP (n=40) | LDPS (n=75) | p value |
|--------------------------|-------------|-------------|---------|
| Clinical characteristics  |             |             |         |
| Age (yr)                 | 49.18±15.08 | 53.11±15.65 | 0.196   |
| Sex, male                | 13 (32.5)   | 27 (36.0)   | 0.707   |
| BMI (kg/m²)              | 22.55±3.44  | 24.07±3.60  | 0.031*  |
| Diagnosis                |             |             | 0.098   |
| IPMN                     | 5           | 14          |         |
| NET                      | 10          | 18          |         |
| SPN                      | 8           | 11          |         |
| MCN                      | 11          | 6           |         |
| SCN                      | 1           | 5           |         |
| Metastatic cancer        | 1           | 4           |         |
| Chronic pancreatitis     | 3           | 5           |         |
| Other benign             | 1           | 10          |         |
| Other cancer             | 0           | 2           |         |
| Tumor size (cm)          | 3.68±2.82   | 3.69±2.26   | 0.980   |
| Surgical outcomes        |             |             |         |
| Operation time (min)     | 216.8±65.5  | 216.2±88.7  | 0.973   |
| Hospital stay (days)     | 8.7±4.6     | 9.1±3.8     | 0.684   |
| Estimated blood loss (mL)| 104.3±112.1 | 144.5±161.7 | 0.121   |
| Transfusion              | 0 (0.0)     | 0 (0.0)     |         |
| Complication             | 9 (22.5)    | 30 (40.0)   | 0.059   |
| G1+G2                    | 8 (20.0)    | 27 (36.0)   | 0.999   |
| G3+G4                    | 1 (2.5)     | 3 (4.0)     |         |
| POPF                     | 15 (37.5)   | 28 (37.3)   | 0.986   |
| CR-POPF                  | 0 (0.0)     | 2 (2.7)     | 0.542   |

LSpDP, laparoscopic spleen-preserving distal pancreatectomy; LDPS, laparoscopic distal pancreatectomy; BMI, body mass index; IPMN, intraductal papillary mucinous neoplasm; NET, neuroendocrine tumor; SPN, solitary pseudopapillary neoplasm; MCN, mucinous cystic neoplasm; SCN, serous cystic neoplasm; POPF, postoperative pancreatic fistula; CR-POP, clinically relevant POPF.

*pStatistically significant.

Data are presented as mean±standard deviation, n (%), or number only.

---

**Fig. 3. Immunologic profile following distal pancreatectomy.** The two groups showed no significant differences in all of the immunologic markers. LSpDP, laparoscopic spleen-preserving distal pancreatectomy; LDPS, laparoscopic distal pancreatosplenectomy.
tions and LSpDP with more vascular complications, all with a minimal clinical impact. Both methods showed similar functional outcomes. They concluded that either LDPS or LSpDP could be performed depending on the indication and surgeon’s experiences, considering the comparable results.

In this study, we divided the patient groups into Era 1 and Era 2, and found no statistical differences in clinical characteristics between the two groups. In surgical outcomes, LSpDP group showed superior results in Era 1; however, in Era 2, LDPS group showed equivalent surgical outcomes to LSpDP group. These results suggest that the potential benefit of spleen preservation in surgical outcomes has diminished as time passes, as a result of advances in laparoscopic techniques and postoperative care. In technical aspect, we developed a modified lasso technique for LDPS, which was reported to be feasible, easy, and safe for improving perioperative outcomes in LDPS. Recently, Early Recovery After Surgery has suggested early drain removal, early diet build-up, and early discharge after pancreatic surgery; and in line with these changes, postoperative management at our institution has changed to the use of open drain, early drain removal, and early diet build-up. We cautiously assume that the improvement in POPF rate is due to the change in postoperative management. CR complication (Clavien-Dindo classification grade II or IV) accounted for only 4.0% (3 of 75 patients) of LDPS group in Era 2. The CR complications of three patients were two cases of reoperation due to the peritonitis of unknown origin and one case of reoperation due to the wound dehiscence. As a result, the ratio of LDPS at our institution gradually increased compared to LSpDP, as the time passed from Era 1 to Era 2.

Several studies used immunoglobulin levels to evaluate immunologic function after splenectomy, such as IgG, IgA, and IgM. These studies reported that the level of IgG and IgA increased normally and the level of IgM was normal or decreased after splenectomy. In the present study, similar tendency was observed; however there was no statistical differences in immunologic markers between LSpDP and LDPS groups. Among the patients who underwent LDPS and were followed up for immunologic markers, five patients were re-admitted due to infectious disease. Three patients were admitted due to pneumonia, one patient due to herpes zoster, and the other one patient due to unknown origin. However, in additional analysis comparing the immunologic markers between patients re-admitted due to infectious disease and the others, we failed to find differences in immunologic markers. We carefully conclude that splenectomy does not affect immunologic markers, and that low immunologic markers do not make them more susceptible to infection. Further studies on spleen and immunology should be performed in the future.

In the past, in consideration of the clinical usefulness of spleen preserving robots were used to maximize the success rate of spleen preservation. However, according to recent meta-analyses, the usefulness of robots in spleen preservation was reported to be similar to that of laparoscopy, and we authors also confirmed this in previous research. Rather, it was thought that the robots would be more useful in performing single-site plus one port DP, a concept of reduced port, in well-selected patients during DP requiring concomitant splenectomy. Further research is required regarding the application of robotic surgery on DP.

This study was mainly limited by its retrospective design, which can limit interpretation of the results. Also, there is a possibility that the surgeon factor may have influenced the surgical outcomes of LDPS. The patients enrolled in this study were operated on by four surgeons at a single institution; therefore, the development of learning curve for the surgeons may have affected the surgical outcomes of LDPS and acted as a confounding factor. Alternatively, multicenter retrospective data with propensity score matching analysis could be an option to overcome these issues.

Based on the results, we carefully conclude that during laparoscopic DP, combined splenectomy can be equivalent to spleen preserving in surgical and immunological outcomes, and inevitable splenectomy can be safely conducted.

**AUTHOR CONTRIBUTIONS**

Conceptualization: Chang Moo Kang and Ho Kyoung Hwang. Data curation: Seung Soo Hong and Sung Whan Cha. Formal analysis: Seung Soo Hong and Sung Whan Cha. Investigation: Seung Soo Hong. Methodology: Ho Kyoung Hwang. Project administration: Chang Moo Kang and Woo Jung Lee. Resources: Seung Soo Hong. Software: Seung Soo Hong. Supervision: Chang Moo Kang and Woo Jung Lee. Validation: Chang Moo Kang. Visualization: Ho Kyoung Hwang. Writing—original draft: Seung Soo Hong and Sung Whan Cha. Writing—review & editing: Seung Soo Hong. Approval of final manuscript: all authors.

**ORCID iDs**

Seung Soo Hong https://orcid.org/0000-0001-9913-8437
Sung Whan Cha https://orcid.org/0000-0001-5340-0225
Ho Kyoung Hwang https://orcid.org/0000-0003-4064-7776
Woo Jung Lee https://orcid.org/0000-0001-9273-261X
Chang Moo Kang https://orcid.org/0000-0002-5382-4658

**REFERENCES**

1. Juo YY, King JC. Robotic-assisted spleen preserving distal pancreatectomy: a technical review. J Vis Surg 2017;3:139.
2. Bonavina L. Spleen-preserving laparoscopic distal pancreatectomy: is it worthwhile? Laparosc Surg 2019;3:28.
3. Adam JM, Jacquin A, Laurent C, Collet D, Masson B, Fernández-Cruz L, et al. Laparoscopic spleen-preserving distal pancreatectomy: splenic vessel preservation compared with the Warshaw technique. JAMA Surg 2013;148:246-52.
4. Shoup M, Brennan MF, McWhite K, Leung DH, Klimstra D, Conlon KC. The value of splenic preservation with distal pancreatectomy. Arch Surg 2002;137:164-8.
5. Milito P, Aiolfi A, Asti E, Rausa E, Bonitta G, Bonavina L. Impact of
splen preserving laparoscopic distal pancreatectomy on postoperative infectious complications: systematic review and meta-analysis. J Laparoendosc Adv Surg Tech A 2019;29:167-77.
6. Kim SC, Park KT, Hwang JW, Shin HC, Lee SS, Seo DW, et al. Comparative analysis of clinical outcomes for laparoscopic distal pancreatic resection and open distal pancreatic resection at a single institution. Surg Endosc 2008;22:2261-8.
7. Mabrut JY, Fernandez-Cruz L, Azagra JS, Bassi C, Delvaux G, Weerts J, et al. Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery 2005;137:597-605.
8. Melotti G, Butturini G, Piccoli M, Casetti L, Bassi C, Mullerlin B, et al. Laparoscopic distal pancreatectomy: results on a consecutive series of 56 patients. Ann Surg 2007;246:77-82.
9. Palanivelu C, Shetty R, Jari K, Sendhilkumar K, Rajan PS, Maheshkumar GS. Laparoscopic distal pancreatectomy: results of a prospective non-randomized study from a tertiary center. Surg Endosc 2007;21:373-7.
10. Fernández-Cruz L. Distal pancreatic resection: technical differences between open and laparoscopic approaches. HPB (Oxford) 2006:8:49-56.
11. Wilkins BS. The spleen. Br J Haematol 2002;117:265-74.
12. Okabayashi T, Hanazaki K. Overwhelming postsplenectomy infection syndrome in adults—a clinically preventable disease. World J Gastroenterol 2008;14:176-9.
13. Dumitrascu T, Dima S, Stroescu C, Scarlat A, Ionescu M, Popescu I. Clinical value of spleen-preserving distal pancreatectomy: a case-matched analysis with a special emphasis on the postoperative systemic inflammatory response. J Hepatobiiliary Pancreat Sci 2014;21:654-62.
14. Kwon W, Jang JY, Kim JH, Chang YR, Jung W, Kang MJ, et al. An analysis of complications, quality of life, and nutritional index after laparoscopic distal pancreatectomy with regard to spleen preservation. J Laparoendosc Adv Surg Tech A 2016;26:335-42.
15. Kawasaki Y, Hwang HK, Kang CM, Natsugoe S, Lee WJ. Improved perioperative outcomes of laparoscopic distal pancreatectomy: modified lasso technique. ANZ J Surg 2018;88:886-90.
16. Gustafsson JO, Scott MJ, Hubner M, Nygren J, Demartines N, Francis N, et al. Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations: 2018. World J Surg 2019;43:659-95.
17. Darzi AA, Kamali S, Khakazd M. Influence of splenectomy on immunoglobulins and complement components in major thalassemia. Caspian J Intern Med 2015;6:30-3.
18. Kiani-Amin M, Daneshi M, Ayazi P, Mohammadian S, Rezaei N. Serum immunoglobulin levels in splenectomized and non-splenectomized patients with major Beta-thalassemia. Iran J Pediatr 2011;21:95-8.
19. Fujita T, Matai K, Kohno S, Itsuko K. Impact of splenectomy on circulating immunoglobulin levels and the development of postoperative infection following total gastrectomy for gastric cancer. Br J Surg 1996;83:1776-8.
20. Kang CM, Chung YE, Jung MJ, Hwang HK, Choi SH, Lee WJ. Splenic vein thrombosis and pancreatic fistula after minimally invasive distal pancreatectomy. Br J Surg 2014;101:114-9.
21. Choi SH, Seo MA, Hwang HK, Kang CM, Lee WJ. Is it worthwhile to preserve adult spleen in laparoscopic distal pancreatectomy? Perioperative and patient-reported outcome analysis. Surg Endosc 2012;26:3149-56.
22. Shi N, Liu SL, Li YT, You L, Dai MH, Zhao YP. Splenic preservation versus splenectomy during distal pancreatectomy: a systematic review and meta-analysis. Ann Surg Oncol 2016;23:365-74.
23. Kang CM, Kim DH, Lee WJ, Chi HS. Conventional laparoscopic and robot-assisted spleen-preserving pancreatectomy: does da Vinci have clinical advantages? Surg Endosc 2011;25:2004-9.
24. Kamarajah SK, Sutandi N, Robinson SR, French JJ, White SA. Robotic versus conventional laparoscopic distal pancreatic resection: a systematic review and meta-analysis. HPB (Oxford) 2019;21:1107-18.
25. Gavriliidis P, Roberts KJ, Sutcliffe RP. Comparison of robotic vs laparoscopic vs open distal pancreatectomy. A systematic review and network meta-analysis. HPB (Oxford) 2019;21:1268-76.
26. Yang SJ, Hwang HK, Kang CM, Lee WJ. Revisiting the potential advantage of robotic surgical system in spleen-preserving distal pancreatectomy over conventional laparoscopic approach. Ann Transl Med 2020;8:188.
27. Kim SH, Kang CM, Lee WJ. Robotic single-site plus ONE port distal pancreatectomy. Surg Endosc 2017;31:4258-9.
28. Chong JU, Kang CM. Robotic single-site plus one port: pancreas enucleation. J Gastrointest Surg 2019;23:1527-8.
29. Han HJ, Kang CM. Reduced port minimally invasive distal pancreatectomy: single-port laparoscopic versus robotic single-site plus one-port distal pancreatectomy. Surg Endosc 2019;33:1091-9.
30. Park G, Choi SH, Lee JH, Lim JH, Lee H, Lee JH, et al. Safety and feasibility of robotic reduced-port distal pancreatectomy: a multicenter experience of a novel technique. J Gastrointest Surg 2020;24:2015-20.